Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Hepatitis C combination given green light

  • Comment

A new combination therapy for treating hepatitis C has been approved by the European Commission.

Schering-Plough’s 48-week standard-dose peginterferon alfa-2b, 1.5 mcg/kg once weekly (ViraferonPeg) and ribavirin, 800-1,400 mg daily (Rebetol) combination therapy has been approved for retreating adult patients whose initial treatment did not result in a sustained response.

It is the first and only pegylated interferon combination therapy approved in the EU for retreating hepatitis C relapsers and non-responders.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs